| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 10-28-2025 | 09-30-2025 | 10-Q | |
| 2 | 07-29-2025 | 06-30-2025 | 10-Q | |
| 3 | 05-06-2025 | 03-31-2025 | 10-Q | |
| 4 | 03-25-2025 | 12-31-2024 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $26 to $33.
Stifel analyst Jonathan Block reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $26 to $31.
Truist Securities analyst Richard Newitter reiterates Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from...
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target f...
Beta Bionics (NASDAQ:BBNX) raises FY2025 sales outlook from $88.000 million-$93.000 million to $96.500 million vs $91.355 milli...
Beta Bionics (NASDAQ:BBNX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.44) ...
